<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672655</url>
  </required_header>
  <id_info>
    <org_study_id>56922</org_study_id>
    <secondary_id>1K23DK119470-01</secondary_id>
    <nct_id>NCT04672655</nct_id>
  </id_info>
  <brief_title>Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) RCT</brief_title>
  <acronym>ONBOARD</acronym>
  <official_title>Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molly Tanenbaum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a comprehensive, multicomponent behavioral intervention package (ONBOARD;&#xD;
      OvercomiNg Barriers &amp; Obstacles to Adopting Diabetes Devices). ONBOARD will provide adults&#xD;
      with T1D the skills to maximize benefit and minimize daily interference from barriers&#xD;
      associated with Continuous Glucose Monitoring (CGM) and increase readiness for closed loop.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll 178 adults with T1D between 18-50 years of age. Participants&#xD;
      must not have been using CGM regularly for past 6 months. Once consented and enrolled,&#xD;
      baseline demographic and psychosocial data will be obtained. Participants will receive 12&#xD;
      weeks of CGM supplies at no cost to them and provided with initial standard CGM introduction&#xD;
      and education. Participants will then be randomized to receive ONBOARD or CGM-only. Those&#xD;
      randomized to the ONBOARD condition will schedule 4 60-minute sessions with study&#xD;
      interventionist (every 2 weeks). Hemoglobin A1c values, CGM usage data, and psychosocial data&#xD;
      will be collected at baseline, 3-months (post-intervention), and 6- and 12-months&#xD;
      post-baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will then be randomized to receive ONBOARD or CGM-only. Those randomized to the ONBOARD condition will schedule 4 60-minute sessions with study interventionist (every 3 weeks).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c (HbA1c) over time</measure>
    <time_frame>baseline, month 3, month 6, month 12</time_frame>
    <description>Glycemic control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in glucose target range</measure>
    <time_frame>baseline, month 3, month 6, month 12</time_frame>
    <description>Percent of glucose readings from CGM system between 70-180 mg/dL per unit of time All time points taken together are needed to evaluate this outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent days wearing CGM</measure>
    <time_frame>baseline, month 3, month 6, month 12</time_frame>
    <description>We will use date from CGM to calculated % of days while participating in the study that participants wear the device All time points taken together are needed to evaluate this outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS)</measure>
    <time_frame>baseline, month 3, month 6, month 12</time_frame>
    <description>The T1-DDS is a 28-item self-report scale that assesses multiple dimensions of diabetes distress.&#xD;
Minimum score=1; Maximum score=6; higher scores indicate more distress (worse outcome) All time points taken together are needed to evaluate this outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Monitoring System Satisfaction Survey - Version: Type 1 Diabetes (GMSS-T1D)</measure>
    <time_frame>baseline, month 3, month 6, month 12</time_frame>
    <description>The GMSS-T1D is a 15-item self-report scale that assesses attitudes towards one's current glucose monitoring system.&#xD;
Minimum score=1; Maximum score=5; higher scores indicate greater satisfaction (better outcome) All time points taken together are needed to evaluate this outcome measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>ONBOARD Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those randomized to the ONBOARD condition will receive the intervention which consists of four 60-minute sessions with study interventionist. Each session will be scheduled two weeks apart from each other.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CGM Only Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Those randomized to the CGM Only group will not receive the ONBOARD intervention during their 12-month participation in the study. There will only receive 12 weeks of CGM supplies and provide A1Cs, data downloads, and survey responses during various time points in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ONBOARD</intervention_name>
    <description>Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM &amp; social situations; Session 4: Building trust with your CGM</description>
    <arm_group_label>ONBOARD Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is age 18-50 years at time of enrollment&#xD;
&#xD;
          2. Subject must not have been using CGM regularly for past 6 months&#xD;
&#xD;
          3. Subject has a clinical diagnosis of type 1 diabetes&#xD;
&#xD;
          4. Subject comprehends spoken and written English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a medical disorder that in the judgment of the investigator will interfere&#xD;
             with completion of any aspect of the protocol.&#xD;
&#xD;
          2. Subject has a neurologic disorder that in the judgment of the investigator will affect&#xD;
             completion of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Molly Tanenbaum, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly Tanenbaum, PhD</last_name>
    <phone>6507253955</phone>
    <email>mollyt@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Ngo, BS</last_name>
    <phone>(650) 723-3659</phone>
    <email>jessngo@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Tanenbaum, PhD</last_name>
      <phone>650-725-3955</phone>
      <email>mollyt@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Clara Nachmanoff</last_name>
      <phone>650-723-0702</phone>
      <email>cgnach@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Korey Hood, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Basina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Molly Tanenbaum</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

